# TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

> **NCT07639879** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Tarapeutics Science Inc.** · enrollment: 180 (estimated)

## Conditions studied

- PTCL
- NK T-Cell Lymphoma

## Interventions

- **DRUG:** TR115
- **DRUG:** Investigator's Choice

## Key facts

- **NCT ID:** NCT07639879
- **Lead sponsor:** Tarapeutics Science Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2029-07-30
- **Final completion:** 2030-07-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639879, "TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07639879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*